We have read with interest the comments by Núñez et al, which contribute to the interpretation of the results of our work, published in Revista Española de Cardiología.1 We acknowledge the inherent limitations due to our not using Cox proportional hazards regression or Cox regression. With an absolute number of 34 cardiovascular deaths and 113 readmissions for heart failure, in the absence of follow-up time, the study design did not permit calculation of the incidence of events. For this reason, we decided on multivariable logistic regression for the analysis. To include the confounding variables and effect modifiers when building the logistic regression model, we first performed an analysis to identify those that could have an influence on the final event. We agree with Núñez et al that, as a consequence of the limited number of patients included in the study and the large number of variables that we ultimately considered introducing in the multivariable model, the results presented could have affected the external validity of the study. Consequently, the statistical model used may partly be responsible for our not corroborating in our patient population either the benefits in terms of a reduction in new hospital admissions among the heart failure patients treated with rosuvastatin, observed in the post hoc analysis of the CORONA trial,2 or the benefits in terms of survival, mainly with lipophilic statins (97% atorvastatin), observed in the real world.3 As occurred in the latter study,3 in our study, access to levels of the amino-terminal fraction of pro-brain natriuretic peptide was limited to only a small number of patients, which may have prevented us from examining whether those with higher values benefit less from statin therapy, as appears to occur with both hydrophilic4 and lipophilic5 statins.
ISSN: 1885-5857
Impact factor 2023
7.2